CYP19A1 and bone fracture: Second, although we adjusted for aromatase inhibitor use (prevalence rate ranged from 9.36% to 14.08% in patients without and with a bone fracture) in our study, information on osteoporosis screening, bisphosphonate use, and compliance with concurrent guidelines for osteoporosis prevention was unavailable, which may bias our findings.